Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival.

Trial Details

NCT ID
NCT05969496
Phase
PHASE2
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Axitinib
  • Pembrolizumab
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Highlands Ranch, Colorado, United States|39.55388,-104.96943
  • Lone Tree, Colorado, United States|39.55171,-104.8863

Key Eligibility Criteria

  • Provision to sign and date the consent form.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Participant self-identified gender ages \>/= 18 years old is acceptable and appropriate if they meet other inclusion criteria.
  • Histologically proven clear cell component RCC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →